Normal view

STAT
STAT+: The unusual Prasad missive in the FDA’s rejection of the Moderna flu shot application Meghana Keshavan
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. So: Moderna says it was blindsided by the FDA, and Vinay Prasad, on its mRNA flu vaccine. Meanwhile, regulators are moving aggressively against Hims & Hers, and midsized biotechs have come together in solidarity — saying they could be crushed by President Trump’s drug pricing policy. Needless to say, it is not business as usual in Washington. Out west, STAT’s Jona
11 February 2026 at 22:45

STAT+: The unusual Prasad missive in the FDA’s rejection of the Moderna flu shot application

STAT

11 February 2026 at 22:45

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

So: Moderna says it was blindsided by the FDA, and Vinay Prasad, on its mRNA flu vaccine. Meanwhile, regulators are moving aggressively against Hims & Hers, and midsized biotechs have come together in solidarity — saying they could be crushed by President Trump’s drug pricing policy. Needless to say, it is not business as usual in Washington.

Out west, STAT’s Jonathan Wosen spoke with Novartis’ chief of biomedical research, who was in San Diego for the groundbreaking on a $1.1 billion research hub. She explained why company is pruning its pipeline and how it’s harnessing AI.

Continue to STAT+ to read the full story…